linjc16/ctgov huggingface dataset:
Postpartum Experience by the Second Parent

Study Overview
=================
Brief Summary
-----------------
Many studies have been performed on mothers and their postnatal experiences. Unfortunately, studies about the second parent are very rare. Second parent is yet an essential figure in the parent-child triad and a real support for the mother. The postpartum period is a time of intense restructuring and upheaval, both physically and psychologically. Studies have shown that almost 13% of fathers suffer from depression.

Detailed Description
-----------------
The main objective is to describe the postpartum experience of the second parent.

Official Title
-----------------
Postpartum Experience by the Second Parent

Conditions
-----------------
Postpartum Experience

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females Second parent of a child born living for at least 3 months and at most 6 months Major Agreeing to participate in the study Exclusion Criteria: Minors Protected by law (guardianship, curatorship, safeguarding of justice) Not agreeing to participate in this study Parents of stillborn children Refusing to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The second parent of a child<br>The second parent of a child born since minimum 3 months and maximum 6 months. | Other: data collection<br>* Data collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Experience of the postpartum by the second parent | This experience of the postpartum by the second parent will be evaluated by a Likert scale with 5 proposals: Very good experience/ Good experience/ Lived/neutral/ Bad experience/ Very bad experience | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
postpartum experience, second parent
Natural History Study of Patients With HPDL Mutations

Study Overview
=================
Brief Summary
-----------------
This study uses medical records that allow retrospective data extraction of clinical manifestation to assess the natural history of HPDL mutations

Detailed Description
-----------------
A novel mitochondrial disease arises from mutations in HPDL, which codes for 4-hydroxyphenylpyruvate dioxygenase-like protein. The main purpose of this study is to establish a patient registry to gather medical data from consenting HPDL mutation patients worldwide. From longitudinal data, we will be able to figure out the natural history of the disease, and genotype-phenotype correlation. Dry blood spots will be collected to develop biomarkers to understand the disease better.

Official Title
-----------------
A Patient Registry and Natural History Study of Patients With Biallelic HPDL Mutations

Conditions
-----------------
Mitochondrial Encephalomyopathies, Hereditary Spastic Paraplegia, Spastic Paraplegia, White Matter Disease, Neonatal Encephalopathy, Mutation, Genetic Disease

Intervention / Treatment
-----------------
* Other: Patient Registry
* Other: Dry blood spots sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any individuals diagnosed with HPDL variants Clinical diagnosis can include: HPDL-related hereditary spastic paraplegia (HSP) HPDL-related neonatal mitochondrial encephalopathy Spastic paraplegia -83 (SPG83) Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities (NEDSWMA) Exclusion Criteria: Any known genetic abnormality (other than HPDL mutation) Any condition that, in the opinion of the Site Investigator, could put the participant at undue risk and/or would ultimately prevent the completion of study procedures
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HPDL deficiency<br>Patients with HPDL mutations | Other: Patient Registry<br>* Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.<br>Other: Dry blood spots sampling<br>* Dry blood splots require 500nl of blood.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinician questionnaire | Clinician-reported clinical and genetic confirmation of HPDL mutations | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPDL, HPDL related neonatal mitochondrial encephalopathy, HPDL related hereditary spastic paraplegia, Spastic paraplegia-83, Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities
MCG Discovery Study in Emergency Departments

Study Overview
=================
Brief Summary
-----------------
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question it aims to answer is whether interpretable data can be reliably collected as part of an ED workflow.

Official Title
-----------------
Discovery Study of Using a Magnetocardiography (MCG) Device at Emergency Departments (EDs)

Conditions
-----------------
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI

Intervention / Treatment
-----------------
* Device: Sponsor MCG device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presents to ED with symptoms of Acute Coronary Syndrome (ACS) Can provide written consent Exclusion Criteria: Presents to ED with ST-Elevation Myocardial Infarction (STEMI) Presents to ED with Atrial Fibrillation Clear non-ischemic cause for symptoms (i.e. trauma) Active thoracic metal implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sponsor MCG device<br>All participants will receive a scan from the Sponsor MCG device | Device: Sponsor MCG device<br>* unshielded device measuring cardiac magnetic fields<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % analyzable Sandbox MCG data | % Sandbox MCG data collected and suitable for analysis | during the procedure (MCG scan) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sandbox MCG safety | Device-related adverse events | 30 days | 
| Characterization of scan results that may differentiate between high risk and low risk ACS patients | Signal Noise Ratio of ECG features | during the procedure (MCG scan) | 
| Characterization of scan results that may differentiate between high risk and low risk ACS patients | t-wave field maximum angle | during the procedure (MCG scan) | 
| Characterization of scan results that may differentiate between high risk and low risk ACS patients | heartbeats needed to obtain signal | during the procedure (MCG scan) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MCG, magnetocardiography
Clinical Evaluation of the PowerGlide™ Pro Midline Catheter

Study Overview
=================
Brief Summary
-----------------
Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases

Detailed Description
-----------------
Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases. The selected patients are in need of a long-term i.v. therapy for reasons as antibiotic therapy or alprostadil therapy. The Midline catheter is a device, which is placed via Seldinger's technique to a vein usual on the upper extremity under ultrasound-control.

Official Title
-----------------
Clinical Evaluation of the PowerGlide™ Pro Midline Catheter

Conditions
-----------------
Pain, Catheter Infection

Intervention / Treatment
-----------------
* Device: PowerGlide™ Pro Midline Catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: need for i.v. therapy longer than 7 days poor peripheral vein status Administration of alprostadil Exclusion Criteria: pending dialysis allergy to catheter material minor age life threatening conditions requirement for central venous catheter

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dwelling Time | Length of catheter in situ time | 0-29 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Administration of Alprostadil | Feasibility for the usage of Alprostadil measured by patients with development of thrombophlebitis or occlusion | 0-29 days | 
| Catheter Complications | Site complications as thrombophlebitis and occlusion | 0-29 days |
Validation of Accexible as a Tool for Screening and Monitoring Depression.

Study Overview
=================
Brief Summary
-----------------
Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. The present study has the objective of validating Accexible as a tool for Screening and Monitoring Depression.

Official Title
-----------------
Validación Del Sistema de Cribaje y Seguimiento de acceXible Para depresión.

Conditions
-----------------
Major Depressive Disorder (MDD)

Intervention / Treatment
-----------------
* Device: Accexible


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult 18-65 years of age. Participants must have Spanish as their first language (able to speak and understand verbal messages). Participants must have mobile phone with internet. Participants must have the ability to understand AcceXible's basic instructions. Participants must agree to participate in the study and have voluntarily signed the informed consent. Exclusion Criteria for patients: To have received a diagnosis of neurodegeneration. To have significant vision problems that would affect the ability to perceive visual stimuli. To have significant hearing problems that would affect the ability to understand verbal cues. To be unable to give informed consent to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br> | Device: Accexible<br>* Speech Analysis<br>|
| Depression<br> | Device: Accexible<br>* Speech Analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of Depression | questionnaire | An average of 1 year |
Single Lumen Intubation and Heart-Lung Machine (HLM) Mode Ventilation

Study Overview
=================
Brief Summary
-----------------
In this trial, we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade.

Official Title
-----------------
Single Lumen Intubation and Heart-Lung Machine (HLM) Mode Ventilation Study in Endoscopic Thoracic Sympathetic Blockade

Conditions
-----------------
Anesthesia Time

Intervention / Treatment
-----------------
* Procedure: single vs double


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 135 patients underwent bilateral ETSB procedure under general anesthesia Exclusion Criteria: patients who underwent one sided ETSB patients under the age of 18 Patients over 65 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: double lumen tube<br>In the DLT group, the lung on the side to be treated was distinguished from the ventilator and extinguished and single lung ventilation was performed with the other lung. | Procedure: single vs double<br>* we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade<br>|
| Active Comparator: single lumen tube<br>In the SLT group, after thoracoscopic input, the anesthetist was in contact with the surgeon and his lung pressures were reduced manually until the lowest pressure, where the surgeon's vision was optimal. | Procedure: single vs double<br>* we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anesthesia time | anesthesia time during intubation | 1 year |
Cardiovascular Assessment of Pediatric Cancer Survivors

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to evaluate cardiac and vascular health status of pediatric cancer survivors.

Detailed Description
-----------------
All pediatric cancer survivors were evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.

Official Title
-----------------
Cardiovascular Assessment of Pediatric Cancer Survivors: Understanding Long-Term Effects and Risks

Conditions
-----------------
Left Ventricular Dysfunction, Heart Failure

Intervention / Treatment
-----------------
* Diagnostic Test: ECG, Echocardiography, cTnI, NT-ProBNP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed cancer at pediatric age Exclusion Criteria: Having cancer after 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of LV Dysfunction | Echocardiographic evaluation of left ventricular functions | From the first visit at cardio-oncology division through study completion, an average of 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Childhood Cancer Survivors, Cardiotoxicity, cancer treatment related heart diseases
Delving Into Participation Patterns in Social Anxiety Studies

Study Overview
=================
Brief Summary
-----------------
The study seeks to delve into the firsthand experiences of patients diagnosed with social anxiety who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future social anxiety patients and play an active role in advancing medical research.

Official Title
-----------------
Delving Into Participation Patterns in Social Anxiety Clinical Trials and Investigating Engagement Trends Among Individuals Impacted by the Disease

Conditions
-----------------
Social Anxiety

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has self-identified as planning to enroll in a clinical trial Patient has been diagnosed with social anxiety Patient is a minimum of 18 years or older Exclusion Criteria: Patient does not understand, sign, and return consent form Inability to perform regular electronic reporting Patient is pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to participate in a social anxiety clinical trial |  | 3 months | 
| Rate of patients who remain in social anxiety clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
social anxiety
Prediction on the Recurrence of Manic and Depressive Episodes in Bipolar Disorder

Study Overview
=================
Brief Summary
-----------------
Mood disorders (including bipolar disorder and major depressive disorder) are chronic mental disorders with high recurrent rate. The more the number of recurrence is, the worse long-term prognosis is. This study aims to establish a prediction model of recurrence of manic and depressive episodes in mood disorders, with a hope to detect recurrence relapse as early as possible for timely clinical intervention. We will adopt wearable smart watch to collect heart rate, sleep pattern, activity level, as well as emotional status for one year long in 100 patients with bipolar disorder, and annotated their mood status (i.e., manic episode, depressive episode, and euthymic state). We expect to establish prediction models to predict the recurrence of mood episodes.

Official Title
-----------------
Prediction on the Recurrence of Manic and Depressive Episodes in Bipolar Disorder

Conditions
-----------------
Bipolar Disorder, Depressive Disorder

Intervention / Treatment
-----------------
* Device: Wearable activity tracker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-5 Bipolar disorder or depressive disorder 20 60 years old Willing to carry smartwatch and smartphone most of the time Exclusion Criteria: Comorbid with substance use disorder Unable to use smartwatch and smartphone

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BP<br>100 patients with mood disorders from the psychiatric ward and outpatient services of the Department of Psychiatry, National Taiwan University Hospital | Device: Wearable activity tracker<br>* Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development and verification of mood episode prediction algorithm | Collected data will apply to learning algorithm, random forest, which constructs a multitude of decision trees at training time and outputting a class that is the mode of the classes of the individual trees. Performance of the trained prediction model was evaluated by assessing the model's accuracy, sensitivity, specificity, and the area under the curve. In a machine learning evaluation process, a part of data is used for model training, and the other portion is used for model testing. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biomarker, Bipolar disorder